Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunization elicit high neutralizing antibody generation and mucosal IgA...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavda, Vivek P., Vora, Lalitkumar K., Pandya, Anjali K., Patravale, Vandana B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Keynote (Green)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319039/
https://www.ncbi.nlm.nih.gov/pubmed/34332100
http://dx.doi.org/10.1016/j.drudis.2021.07.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319039/
https://www.ncbi.nlm.nih.gov/pubmed/34332100
http://dx.doi.org/10.1016/j.drudis.2021.07.021

Ejemplares similares